Table 2—

Results of 3-month additional treatment with pioglitazone in the study patients

VariablesControl (n = 66)
Pioglitazone (n = 70)
Baseline3 monthsBaseline3 months
BMI (kg/m2)23.0 ± 0.523.2 ± 0.523.4 ± 0.423.5 ± 0.4
SBP (mmHg)146 ± 2146 ± 3144 ± 2145 ± 2
DBP (mmHg)82 ± 282 ± 281 ± 281 ± 2
FPG (mmol/l)9.4 ± 0.39.2 ± 0.39.6 ± 0.48.0 ± 0.3§
HbA1c (%)8.0 ± 0.27.9 ± 0.28.1 ± 0.17.1 ± 0.1§
IRI (pmol/l)55.9 ± 4.1054.9 ± 4.1057.5 ± 3.9651.7 ± 5.18
HOMA-IR3.30 ± 0.283.20 ± 0.293.35 ± 0.292.25 ± 0.17§
Total cholesterol (mmol/l)5.45 ± 0.165.46 ± 0.175.46 ± 0.105.33 ± 0.10
LDL cholesterol (mmol/l)3.32 ± 0.113.33 ± 0.123.30 ± 0.083.17 ± 0.08*
HDL cholesterol (mmol/l)1.47 ± 0.101.43 ± 0.111.44 ± 0.051.47 ± 0.05
Triglycerides (mmol/l)1.55 ± 0.041.57 ± 0.061.56 ± 0.041.50 ± 0.04
Adiponectin (μg/ml)6.08 ± 0.426.06 ± 0.396.03 ± 0.347.82 ± 0.52
Leptin (ng/ml)6.56 ± 0.456.58 ± 0.456.52 ± 0.506.63 ± 0.46
  • Data are means ± SEM.

  • *

    * P < 0.05,

  • P < 0.01 vs. baseline values;

  • P < 0.05,

  • §

    § P < 0.01 vs. control.